134 related articles for article (PubMed ID: 24926553)
1. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?
Marcq M; Vallée A; Bizieux A; Denis MG
J Thorac Oncol; 2014 Jul; 9(7):e49-e50. PubMed ID: 24926553
[No Abstract] [Full Text] [Related]
2. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
5. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
6. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
Wu YL; Sequist LV; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; Yang JC
Br J Cancer; 2017 Jan; 116(2):175-185. PubMed ID: 28006816
[TBL] [Abstract][Full Text] [Related]
7. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.
Brevet M; Johnson ML; Azzoli CG; Ladanyi M
Lung Cancer; 2011 Jul; 73(1):96-102. PubMed ID: 21130517
[TBL] [Abstract][Full Text] [Related]
8. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
10. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Abe T; Ureshino N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
J Thorac Oncol; 2011 Oct; 6(10):1639-48. PubMed ID: 21921847
[TBL] [Abstract][Full Text] [Related]
11. The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
Sárosi V; Balikó Z; Smuk G; László T; Szabó M; Ruzsics I; Mezősi E
Pathol Oncol Res; 2016 Oct; 22(4):755-61. PubMed ID: 27105879
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
Zhang C; Wei B; Li P; Yang K; Wang Z; Ma J; Guo Y
PLoS One; 2017; 12(3):e0173524. PubMed ID: 28333951
[TBL] [Abstract][Full Text] [Related]
13. [Relevance of circulating tumor DNA in lung cancer: A case report].
Amrane K; Le Gac G; Descourt R; Quere G
Rev Mal Respir; 2016 Nov; 33(9):804-807. PubMed ID: 27132215
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
Sorensen BS; Wu L; Wei W; Tsai J; Weber B; Nexo E; Meldgaard P
Cancer; 2014 Dec; 120(24):3896-901. PubMed ID: 25103305
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Mathur G; Ma D
J Thorac Oncol; 2014 Jul; 9(7):e55-e57. PubMed ID: 24926557
[No Abstract] [Full Text] [Related]
16. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma].
Han R; Zhong W; Zhao J; Zhang L; Xia Y; Wang H; Li L; Wang M
Zhongguo Fei Ai Za Zhi; 2011 Feb; 14(2):127-31. PubMed ID: 21342642
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
[TBL] [Abstract][Full Text] [Related]
19. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
[TBL] [Abstract][Full Text] [Related]
20. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
